Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Forty Seven's Capital Expenditure for the
three
months ended in Dec. 2019 was $0.00 Mil. Its Revenue for the
three
months ended in Dec. 2019 was $0.00 Mil.
GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.
Forty Seven Capex-to-Revenue Historical Data
The historical data trend for Forty Seven's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forty Seven's Capex-to-Revenue
For the Biotechnology subindustry, Forty Seven's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's Capex-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Forty Seven's Capex-to-Revenue falls into.
Forty Seven Capex-to-Revenue Calculation
Forty Seven's Capex-to-Revenue for the fiscal year that ended in Dec. 2019 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Forty Seven Capex-to-Revenue Related Terms
Thank you for viewing the detailed overview of Forty Seven's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your 